Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for reducing homosysteine

A technology of homocysteine ​​and composition, which is applied in the pharmaceutical composition for reducing homocysteine ​​and in the field of medicine for living organisms, can solve the problems of not significantly enhancing the effect of folic acid on reducing Hcy, and achieve the reduction of homocysteine The effect of amino acid

Active Publication Date: 2009-04-15
SHENZHEN AUSA PHARMA
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

On the premise of gender standardization and pre-treatment plasma folic acid concentration at 12 nmol / L and Hcy level at 12 μmol / L, the analysis results showed that Hcy concentration decreased when folic acid doses were 0.2, 0.4, 0.8, 2.0 and 5.0 mg per day 13%, 20%, 23%, 23% and 25%; adding vitamin B12 (400μg / day) at the same time can further reduce Hcy by 7%, while adding vitamin B6 does not seem to significantly enhance the effect of folic acid on reducing Hcy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for reducing homosysteine
  • Pharmaceutical composition for reducing homosysteine
  • Pharmaceutical composition for reducing homosysteine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Example 1 Preparation of compound folic acid vitamin B12 creatine tablets (1000 pieces)

[0047] Formula: Folic Acid 0.4g

[0048] Vitamin B12 0.002g

[0049] Creatine 700g

[0050] Microcrystalline Cellulose 100g

[0051] Sodium carboxymethyl starch 60g

[0052] Proper amount of povidone ethanol solution

[0053] Magnesium Stearate 1%

[0054] Preparation method: crush the raw and auxiliary materials through an 80-mesh sieve, and dry for later use. Take 0.4g of folic acid, 0.002g of vitamin B12, and 700g of creatine and mix them uniformly according to the method of equal increments. Ketone K29 / 30-95% ethanol solution to make soft material, granulate with 20-mesh sieve, dry at 40°C for about 2 hours, granulate with 20-mesh sieve, control the water content of the granules to 2-3%, and mix the dried granules with hard Magnesium fatty acid is mixed evenly, and the semi-finished product is detected, and the content is measured, a...

Embodiment 2

[0055] Example 2 Preparation of compound folic acid vitamin B12 creatine granules (1000 bags)

[0056] Formula: Folic Acid 0.4g

[0057] Vitamin B12 0.006g

[0058] Creatine 2000g

[0059] Powdered sugar 7000g

[0060] Sodium carboxymethyl starch 500g

[0061] Aspartame 5g

[0062] 5% povidone ethanol solution appropriate amount

[0063] Macrogol 6000 5%

[0064] Fragrance 1.5%

[0065] Preparation method: crush the raw and auxiliary materials through an 80-mesh sieve, and dry for later use. Take 0.4g of folic acid, 0.006g of vitamin B12, and 2000g of creatine and mix them uniformly according to the method of equal increments. % povidone K29 / 30-95% ethanol solution to make soft material, granulate with 20 mesh sieve, dry at 40°C for about 2 hours, granulate with 20 mesh sieve, control the water content of the granules to be below 1%, and dry the granules Mix evenly with magnesium stearate, test the semi-finished produ...

Embodiment 3～ Embodiment 10

[0066] Embodiment 3 to Embodiment 10 Preparation of compound folic acid granules containing different components and content ratios

[0067] The preparation method is the same as in Example 2, and the granules (1000 bags) are made according to the formula shown in Table 1.

[0068] Table 1 Embodiment 3~10 granule formula composition

[0069]

[0070] Each bag of compound folic acid granules prepared in Example 3 contains 0.8 mg of folic acid, 6 ug of vitamin B12, and 3000 mg of creatine.

[0071] Each bag of compound folic acid granules prepared in Example 4 contains 1 mg of folic acid, 1 mg of vitamin B12, and 4000 mg of creatine.

[0072] Each bag of compound folic acid granules prepared in Example 5 contains 1 mg of folic acid, 1 mg of vitamin B12, and 4000 mg of creatine.

[0073] Each bag of compound folic acid granules prepared in Example 6 contains 0.4 mg of folic acid, 0.006 mg of vitamin B12, 2000 mg of creatine, and 0.5 mg of betaine.

[0074] Each bag of co...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for reducing homocysteine, which comprises the following components: 1) an officinal dosage of folic acid or pharmaceutical salts thereof; 2) an officinal dosage of vitamin B12 or pharmaceutical salts thereof; 3) an officinal dosage of creatine or pharmaceutical salts thereof; and 4) pharmaceutical carriers or excipients. The composition further comprises one or more than one of betaine, VB6, N-acetylcysteine, and riboflavin. The invention also relates to application of the pharmaceutical composition in preparing drugs for reducing the homocysteine as well as the application thereof in preparing the drugs for treating life bodies suffered from hyperhomocysteinemia. The pharmaceutical composition belongs to the field of pharmacy.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for reducing homocysteine, and the use of the pharmaceutical composition in the preparation of drugs for reducing homocysteine ​​and in the preparation and treatment of patients with hyperhomocysteinemia Use in medicine of living organisms. The present invention belongs to the field of pharmacy. Background technique [0002] The results of most meta-analyses show that hyperhomocysteine ​​(Hcy, homocysteine) hyperemia is an important and independent risk factor for cardiovascular and cerebrovascular diseases. Atherosclerotic lesions of coronary arteries and other arteries may appear earlier in patients with hyperhomocysteinemia, which is an independent risk factor for ischemic cardiovascular and cerebrovascular diseases. Boushey et al [JAMA, 1995, 274(8): 10492-10571] conducted a comprehensive analysis of the results of 27 studies and found that elevated tHcy was associated with an increase...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/714A61K31/519A61K31/198A61K31/205A61P9/10A61P9/12
Inventor 刘平王文艳陈明侠秦献辉王燕徐希平
Owner SHENZHEN AUSA PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com